Skip to main content
. 2020 Aug 13;56(2):1901380. doi: 10.1183/13993003.01380-2019

TABLE 1.

Clinical and demographic characteristics in hypersensitivity pneumonitis subgroups

Subjects HPAbs+ Subjects HPAbs p-value
Age years 60 53±9 110 53±12 0.59
Female 60 52 (86) 110 89 (81) 0.39
Duration of symptoms before diagnosis months 60 25 (4–20) 110 27 (2–120) 0.30
Former smokers 60 14 (23) 110 26 (24) 0.96
Exposure to birds 60 47 (78) 110 91 (83) 0.53
Diabetes mellitus 60 11 (18) 110 16 (15) 0.51
Systemic hypertension 60 9 (15) 110 22 (20) 0.53
Dead 54 12 (20) 108 9 (8) 0.02
Antibodies against avian antigens 60 59 (94) 110 57 (53) <0.0001
Unidentified antigen 60 4 (6) 110 50 (47) <0.0001
HRCT chronic pattern 60 48 (80) 110 59 (54) <0.001
C-reactive protein mg·dL−1 60 0.9 (0.02–7.1) 110 0.7 (0.01–3.9) 0.95
BAL# lymphocytosis 49 49±19 87 46±25 0.17
FVC % pred 60 57.8±18 106 53.8±20 0.20
DLCO % pred 49 46±22 85 51±21 0.24
6MWT m 42 333±168 71 333±116 0.21
PO2 mmHg 42 51±8 71 50±13 0.90
PAP§ mmHg 47 39±14 69 38±14 0.40

Data are presented as n, mean±sd, n (%) or median (range), unless otherwise stated. HPAbs+/HPAbs: hypersensitivity pneumonitis with and without autoantibodies, respectively; HRCT: high-resolution computed tomography; BAL: bronchoalveolar lavage; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; 6MWT: 6-min walk test; PO2: oxygen tension; PAP: pulmonary artery pressure. #: performed in 81% of the HPAbs+ patients and 79% of the HPAbs patients; : measured in 42 HPAbs+ patients and 71 HPAbs patients; §: measured by echocardiography in 47 HPAbs+ patients and 69 HPAbs patients.